Pharmacoeconomic analysis fenofibrate + rosuvastatin of fixed combination compare to loose-pill combination in patients with atherogenic dyslipidemia

Abstract

This article presents the results of a pharmacoeconomic analysis of the use of a combination of rosuvastatin + fenofibrate in a single film-coated tablet (“Suprozafen”) and fenofibrate + rosuvastatin in the loose-pill combination of various trade names in the treatment of patients with atherogenic dyslip- idemia. In the pharmacoeconomic evaluation cost-effectiveness analysis and budget impact analysis were used. From the point of view of clinical efficacy, it was found that the fixed combination has an advantage compared to loose-pill combination, expressed in a decrease in the incidence of serious cardiovas- cular events when prescribing a fixed combination of drugs by 8.64%. The results of cost analysis calculations showed that annual cost of of treatment with the fixed combination drug Suprozafen is 11,184 rubles, while treatment with loose-pill combination of rosuvastatin and fenofibrate will be accompa- nied by costs of 10,775 rubles. Thus, the cost of a fixed combination is only 409 rubles. (per year per patient) or 3.7% more higher than when prescrib- ing rosuvastatin and fenofibrate separately, that reflects the comparability of this expenditures. Cost savings for the treatment of serious cardiovascular events when using the fixed combination drug (Suprozafen), which arose due to higher adherence to treatment and a decrease in the risk of these events, is 11,188.9 rubles. per patient per year. Taking into account the results of the cost analysis, the savings in the healthcare system budget for a time hori- zon of one year per 100 patients using a fixed combination of rosuvastatin + fenofibrate is 1,078,001 rubles. The results of the pharmacoeconomic study confirm and allow us to accept the hypothesis that the fixed combination of the drug rosuvastatin and fenofibrate (drug Suprozafen) has a pharmacoeco- nomic advantage compared to the appointment of loose-pill combination. At an almost comparable cost of treatment, the fixed combination, due to higher patient adherence, allows achieving better disease control, reducing the risk of developing serious cardiovascular events and the associated economic burden.